If diarrhea or constipation do not improve or become severe, talk to your healthcare provider as soon as possible
Beyond weight reduction, these medications improve blood sugar control, reduce cardiovascular event risk, and lower inflammatory markers
This information is provided for scientific context only and is not guidance for human use
Retatrutide results from clinical trials show approximately 24.2% weight loss at 48 weeks, compared to roughly 16% with semaglutide (Ozempic/Wegovy) and 22.5% with tirzepatide (Mounjaro/Zepbound) at their respective maximum doses
Clinical guidelines suggest adjusting doses based on individual needs, making it possible to maintain lower doses for comfort and sustained results
However, very long-term data spanning years to decades does not yet exist